AstraZeneca Amends its Development and Commercialization Agreement with Ironwood for Linzess (linaclotide) Signed in 2012 

Shots:

• Ironwood to receive three non-contingent payment of $35M b/w 2021 & 2024, ~$90M as a milestone with royalties on sales of Linzess in China mainland, China Hong Kong and China Macau. AstraZeneca to get full rights to develop, manufacture & commercialize Linzess in China
• In Oct’2012, the companies collaborated to co-develop and co-commercialize Linzess and were jointly responsible for strategic oversight of the development and commercialization of Linzess in China while AstraZeneca had primary responsibility for local operational execution
• Linzess is a guanylate cyclase-C (GC-C) agonist, binds to it leading to an increased intestinal fluid secretion and accelerated transit with a decrease in the activity of pain-sensing nerves in the intestine and has received NMPA’s approval for irritable bowel syndrome with constipation (IBS-C) in Jan’2019 with its expected launch in 2019

Click here to­ read full press release/ article | Ref: AstraZeneca | Image: The Star